Publications by authors named "Michael D Barker"

Claim this Profile
C
Covalent targeting of non-cysteine residues in PI4KIIIβ.
Brett Cosgrove, Emma K Grant, Sophie Bertrand, Kenneth D Down, Don O Somers, Michael D Barker

RSC Chem Biol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence that all Sorsby's fundus dystrophy mutations cause TIMP3 dimerization resulting in impaired inhibition of VEGFR2.
Fatimah A Alsaffar, Ahmed H Mujamammi, Mohammed S K Aldughaim, Martin J H Nicklin, Michael D Barker

Genes Dis· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigating the effects of the core nitrogen atom configuration on the thermodynamic solubility of 6,5-bicyclic heterocycles.
Brett Cosgrove, Kenneth Down, Sophie Bertrand, Nicholas C O Tomkinson, Michael D Barker

Bioorg Med Chem Lett· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coupling of a Novel TIMP3 Peptide to Carboxypeptidase G2 for Pro-Drug Activation at the Tumour Site.
Mohammed S Aldughaim, Fatimah Alsaffar, Michael D Barker

Molecules· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Specific Targeting of PEGylated Liposomal Doxorubicin (Doxil) to Tumour Cells Using a Novel TIMP3 Peptide.
Mohammed S Aldughaim, Munitta Muthana, Fatimah Alsaffar, Michael D Barker

Molecules· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease.
Michael D Barker, John Liddle, Francis L Atkinson, David Matthew Wilson, Marion C Dickson

Bioorg Med Chem Lett· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimisation of a novel series of potent and orally bioavailable azanaphthyridine SYK inhibitors.
Neil S Garton, Michael D Barker, Rob P Davis, Clement Douault, Edward Hooper-Greenhill

Bioorg Med Chem Lett· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives.
Susan M Westaway, Alex G S Preston, Michael D Barker, Fiona Brown, Jack A Brown

J Med Chem· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives.
Susan M Westaway, Alex G S Preston, Michael D Barker, Fiona Brown, Jack A Brown

J Med Chem· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation.
Huw D Lewis, John Liddle, Jim E Coote, Stephen J Atkinson, Michael D Barker

Nat Chem Biol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A peptide derived from TIMP-3 inhibits multiple angiogenic growth factor receptors and tumour growth and inflammatory arthritis in mice.
Yung-Yi Chen, Nicola J Brown, Rita Jones, Claire E Lewis, Ahmed H Mujamammi, Michael D Barker

Angiogenesis· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-Phenyl-7-azaindoles as potent, selective and bioavailable IKK2 inhibitors demonstrating good in vivo efficacy.
John Liddle, Paul Bamborough, Michael D Barker, Sebastien Campos, Chun-Wa Chung

Bioorg Med Chem Lett· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor.
John Liddle, Francis L Atkinson, Michael D Barker, Paul S Carter, Neil R Curtis

Bioorg Med Chem Lett· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lentiviral shRNA knock-down of ADAMTS-5 and -9 restores matrix deposition in 3D chondrocyte culture.
Teresa C Coughlan, Aileen Crawford, Mary B Goldring, Paul V Hatton, Michael D Barker

J Tissue Eng Regen Med· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palladium-catalyzed [1,3]-O-to-C rearrangement of pyrans toward functionalized cyclohexanones.
Julien C R Brioche, Thomas A Barker, David J Whatrup, Michael D Barker, Joseph P A Harrity

Org Lett· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.
Michael D Woodrow, Stuart P Ballantine, Michael D Barker, Beth J Clarke, John Dawson

Bioorg Med Chem Lett· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-Phenyl-7-azaindoles as potent and selective IKK2 inhibitors.
John Liddle, Paul Bamborough, Michael D Barker, Sebastien Campos, Rick P C Cousins

Bioorg Med Chem Lett· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of matrix metalloproteinase-9 against native collagen types I and III.
Heather F Bigg, Andrew D Rowan, Michael D Barker, Tim E Cawston

FEBS J· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorsby's fundus dystrophy mutations impair turnover of TIMP-3 by retinal pigment epithelial cells.
Kevin P Langton, Norman McKie, Brenda M Smith, Nicola J Brown, Michael D Barker

Hum Mol Genet· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of full length ADAMTS6 transcript reveals alternative splicing and a role for the 5' untranslated region in translational control.
Debra J Bevitt, Zheng Li, Jenny L Lindrop, Michael D Barker, Michael P Clarke

Gene· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TIMP3 mutation in Sorsby's fundus dystrophy: molecular insights.
Zheng Li, Michael P Clarke, Michael D Barker, Norman McKie

Expert Rev Mol Med· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of membrane translocating peptides to identify sites of interaction between the C5a receptor and downstream effector proteins.
Graham A Auger, Brenda M Smith, James E Pease, Michael D Barker

Immunology· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of mutant and wild-type TIMP3 in primary gingival fibroblasts from Sorsby's fundus dystrophy patients.
Christine E Arris, Debra J Bevitt, Jeseem Mohamed, Zheng Li, Kevin P Langton, Michael D Barker

Biochim Biophys Acta· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of ADAMTS metalloproteinases in the retinal pigment epithelium derived cell line ARPE-19: transcriptional regulation by TNFalpha.
Debra J Bevitt, Jeseem Mohamed, Jon B Catterall, Zheng Li, Christine E Arris, Michael D Barker

Biochim Biophys Acta· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of cartilage degradation: a combined tissue engineering and gene therapy approach.
Wael Kafienah, Fayza Al-Fayez, Anthony P Hollander, Michael D Barker

Arthritis Rheum· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis